Published in J Clin Pharm Ther on October 21, 2013
Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Drug Saf (2017) 1.11
Adverse Drug Reaction Identification and Extraction in Social Media: A Scoping Review. J Med Internet Res (2015) 0.97
Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br J Clin Pharmacol (2015) 0.96
Patient Participation and the Use of Ehealth Tools for Pharmacoviligance. Front Pharmacol (2016) 0.75
Assessment of Web-Based Consumer Reviews as a Resource for Drug Performance. J Med Internet Res (2015) 0.75
Symptom clusters in women with breast cancer: an analysis of data from social media and a research study. Qual Life Res (2015) 0.75
Interactions between medical residents and drug companies: a national survey after the Mediator® affair. PLoS One (2014) 0.75
Filtering Entities to Optimize Identification of Adverse Drug Reaction From Social Media: How Can the Number of Words Between Entities in the Messages Help? JMIR Public Health Surveill (2017) 0.75
Educating doctors to use drugs well. Br J Clin Pharmacol (1976) 4.33
Prescription of drugs during pregnancy in France. Lancet (2000) 4.12
Assessing reports of therapeutic trials. Br Med J (1970) 3.44
Minimum information needed by prescribers. Br Med J (1978) 3.34
Package inserts for prescribed medicines: what minimum information do patients need? Br Med J (1978) 3.21
Quality of Cochrane reviews: assessment of sample from 1998. BMJ (2001) 3.12
Basic information that prescribers are not getting about drugs. Lancet (1987) 2.31
Drug information: is there a need for international uniformity? Drugs (1974) 2.20
Harnessing placebo effects in health care. Lancet (1994) 2.16
Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain (2000) 2.06
Controlling the NHS drugs budget. BMJ (1994) 2.03
Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf (2006) 1.96
Continuing education in therapeutics: aids to discussions on prescribing. Br Med J (1976) 1.91
Camelford water poisoning accident: serial neuropsychological assessments and further observations on bone aluminium. Hum Exp Toxicol (1993) 1.83
Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. BJU Int (2002) 1.57
[Pharmacovigilance of self-medication]. Therapie (1997) 1.54
Isothiazolinone preservative: cause of a continuing epidemic of cosmetic dermatitis. Lancet (1989) 1.52
[Comparative study of 2 dosage regimens of cefixime in the treatment of otorhinolaryngeal or bronchial infections]. Presse Med (1989) 1.42
Recognising patients' rights: patchy progress. Lancet (1994) 1.39
How did such a bad report get published in the EJCP? Trial of paracetamol, ibuprofen and nimesulide in children with upper respiratory infections (B. Ulukol et al., EJCP November 1999, 55: 615-618) Eur J Clin Pharmacol (2000) 1.39
The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour. BMJ (1998) 1.38
Unwanted effects of pentagastrin. Clin Pharmacol Ther (1971) 1.38
Medicines Act passes crucial test. Lancet (1988) 1.38
Albumin and the Medicines Control Agency. Lancet (1999) 1.37
Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.36
Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards. Int J Health Serv (1993) 1.35
Formulary for self-care. Br J Gen Pract (1994) 1.35
Water drinking and the heart. Lancet (1999) 1.34
Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs (1995) 1.33
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis (2009) 1.30
Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. Br J Clin Pharmacol (2002) 1.27
Sleep attacks and Parkinson's disease treatment. Lancet (2000) 1.25
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol (1986) 1.25
The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients. Brain (1997) 1.23
The European Medicines Evaluation Agency. BMJ (1996) 1.20
Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest (1990) 1.18
Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol (2000) 1.18
Is there a case for an international medical scientific press council? JAMA (1994) 1.18
Commercial partnerships in chronic disease management: proceeding with caution. BMJ (2000) 1.17
Doctors' anxieties in prescribing. J R Coll Gen Pract (1977) 1.17
Measurement of direct photon production in p+p collisions at sqrt[s] = 200 GeV. Phys Rev Lett (2007) 1.16
Effects of yohimbine on submaxillary salivation in dogs. Br J Pharmacol (1989) 1.15
Water--collagen interactions: calorimetric and mechanical experiments. Biopolymers (1978) 1.15
Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol (1992) 1.13
The reliability measurements of lateral scapular slide test at three different degrees of shoulder joint abduction. Br J Sports Med (2008) 1.10
Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. Brain (1989) 1.09
Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy. Trends Pharmacol Sci (1992) 1.09
Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol (2009) 1.08
Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Fundam Clin Pharmacol (2007) 1.07
Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology (2002) 1.07
Yohimbine increases human salivary secretion. Br J Clin Pharmacol (1989) 1.07
Should drug information be an integral part of health care? J R Coll Physicians Lond (1996) 1.07
Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther (1994) 1.04
Many NSAID users who bleed don't know when to stop. BMJ (1998) 1.03
The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther (1992) 1.03
The roles and responsibilities of clinical pharmacology. Br J Clin Pharmacol (1991) 1.03
Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor. Br J Pharmacol (1997) 1.03
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain (1998) 1.03
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord (2001) 1.01
Square wave jerks in parkinsonian syndromes. J Neurol Neurosurg Psychiatry (1991) 1.01
Odorous urine in man after asparagus. Br J Clin Pharmacol (1989) 1.00
Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging (2001) 0.99
Yohimbine increases submaxillary kallikrein release into the saliva in dogs: evidence for alpha 2-adrenoceptor-mediated inhibition of cholinergic pathways. Br J Pharmacol (1991) 0.99
Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin Auton Res (1992) 0.99
[Drug-induced hiccup: a review of the France pharmacologic vigilance database]. Therapie (1999) 0.99
[Pharmacokinetics of cefixime in healthy volunteers after a single oral administration of 200 mg]. Presse Med (1989) 0.98
Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course. Br J Clin Pharmacol (2007) 0.97
Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J Neurol Neurosurg Psychiatry (1994) 0.97
[Septicemia caused by Yersinia enterocolitica. General review apropos of a new case in a young women presenting with thalassemia major]. Rev Med Interne (1982) 0.96
Misuse of the standard error of the mean. Br J Clin Pharmacol (1988) 0.96
[Drug vigilance: opinion survey among residents of a university hospital]. Therapie (1995) 0.96
Misoprostol and illegal abortion in Fortaleza, Brazil. Lancet (1993) 0.95
L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol (1999) 0.94
The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol (1977) 0.94
"Medicamentation" of society, non-diseases and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol (2005) 0.94
Medicine and the Law. Driving under the influence of oxazepam: guilt without responsibility? Lancet (1982) 0.93
Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction (2004) 0.92
The short life of a terminal care support team: experience at Charing Cross Hospital. Br Med J (Clin Res Ed) (1985) 0.92
Drugs and the fetal eye. Lancet (1971) 0.92
Blood dyscrasias attributed to chloramphenicol. A review of 576 published and unpublished cases. Acta Med Scand (1972) 0.92
Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin (2007) 0.91
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm (Vienna) (2003) 0.91
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord (1994) 0.91
Alpha-adrenolytic properties of bromocriptine in dogs. Arch Int Pharmacodyn Ther (1982) 0.91
[Drug-induced alopecia: review of the literature]. Therapie (1995) 0.90
Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study. Vaccine (2011) 0.90
Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res (1991) 0.90
[Cerebral hemodynamics and clinical pharmacology in Parkinson disease]. Therapie (1988) 0.90
Apomorphine test in parkinsonian syndromes. Lancet (1990) 0.90
In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci. Clin Microbiol Infect (2000) 0.90
[Effect of bromocriptine on cerebral blood flow in Parkinson's disease]. Rev Neurol (Paris) (1988) 0.90
Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data. Drug Saf (2000) 0.90
A study of salivary secretion in Parkinson's disease. Clin Neuropharmacol (1999) 0.90
Nicardipine causes sympathetic activation that does not involve baroreceptor reflex tachycardia in conscious sinoaortic-denervated dogs. Eur J Pharmacol (1987) 0.89
The power of placebo. BMJ (1997) 0.89
Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol (1996) 0.88